The Lasting Immunological Footprint of VITT – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Adam Kanack et al, adding:
”Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia
In VITT patients, anti-PF4 antibodies persist as monoclonal/oligoclonal clones without epitope spreading, with one case showing platelet-activating antibodies four years post-event.”
Title: Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia
Authors: Adam Kanack, Emily Mauch, Guillaume Roberge, Noah Splinter, Krishna Gundabolu, Geoffrey Wool, Gemlyn George, Mouhamed Yazan Abou-Ismail, Kristi Smock, David Green, Jonathan Coker, Mindy Kohlhagen, David Murray, Anand Padmanabhan
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 19:00Caitlin Raymond: Can Artificial Blood Solve Blood Supply Shortages?
-
Sep 29, 2026, 18:51Chaza Alaji: Dyslipidemia, Thrombosis and the DIC Diagnostic Trap
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas LangÖ‰ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge